37. D'Amico D, Carbone D, Mitsudomi T, et al. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 1992;7:339-46. 38. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with th e class of p53 gene mutation. Oncogene 1992;7:743-9. 39. Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI. Full -Length Dominant-Negative Survivin for Cancer Immunotherapy. Clin Cancer Res 2003;15:6523-33. 40. Kusmartsev S, Gabrilovich DI. Im mature myeloid cells and cancer -associated immune suppression. Cancer Immunol Immunoth 2002;51:293-8. 41. Gabrilovich D. The mechanisms and functional significance of tumour -induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-52. 42. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96. 43. Zou W, Chen L. Inhibitory B7 -family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-77. 44. Munn DH, Mellor AL. Indoleamine 2,3- dioxygenase and tumor -induced tolerance. J Clin Invest 2007;117:1147-54. 45. Gabrilovich DI, Nagaraj S. Myeloid- derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74. 46. Gabrilovich DI, Ostrand -Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253-68. 47. Peranzoni E, Zilio S, Marigo I, et al. Myeloid -derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010. 48. Ostrand -Ros enberg S, Sinha P. Myeloid- derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182:4499-506. 49. Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte - macrophage colony -stimulation factor -based antitumor vaccine. J Clin Oncol 2007;25:2546- 53.